Theravance Biopharma (NASDAQ:TBPH – Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07, Zacks reports. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.
Theravance Biopharma Trading Down 0.0%
TBPH stock opened at $16.93 on Monday. The firm has a market cap of $872.48 million, a PE ratio of 7.70 and a beta of 0.19. Theravance Biopharma has a 1 year low of $11.20 and a 1 year high of $21.03. The company has a fifty day simple moving average of $16.77 and a 200 day simple moving average of $16.91.
Insider Activity
In other news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total transaction of $642,583.00. Following the transaction, the insider directly owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. This represents a 0.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Theravance Biopharma
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on TBPH. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. JonesTrading lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their price target for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. Finally, BTIG Research downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Eight equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Theravance Biopharma currently has a consensus rating of “Hold” and a consensus target price of $19.40.
Read Our Latest Analysis on Theravance Biopharma
Theravance Biopharma Company Profile
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.
Featured Stories
- Five stocks we like better than Theravance Biopharma
- Symbotic’s Q3 Profit Inflection Signals Underrated Growth Story
- Build Dividend Income at Low Cost With These ETFs
- 3 Major Earnings Winners You May Have Missed
- AI Data Centers Are Splitting Winners From Pretenders in Infrastructure Stocks
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
